A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder

To evaluate the efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD). This was a 10-week (8-week active treatment/2-week post-treatment) randomized, double-blind, placebo- and active-controlled study...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neuropsychiatric disease and treatment 2014-01, Vol.10, p.201-216
Hauptverfasser:	Wang, Gang, McIntyre, Alexander, Earley, Willie R, Raines, Shane R, Eriksson, Hans
Format:	Artikel
Sprache:	eng
Schlagworte:	Antidepressants antidepressive agents (pharmacological action) antipsychotic agents Anxiety Bipolar disorder Clinical medicine clinical trial Clinical trials Diabetes Dosage and administration Double-blind studies Drug dosages Drug therapy FDA approval Major depressive disorder Mental depression Mental disorders Original Research Patient outcomes Phase III Psychiatry Psychotropic drugs Quetiapine Studies Suicides & suicide attempts sustained-release preparations treatment efficacy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To evaluate the efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD). This was a 10-week (8-week active treatment/2-week post-treatment) randomized, double-blind, placebo- and active-controlled study (D1448C00004). Patients received quetiapine XR 150 mg/day, escitalopram 10 mg/day, or placebo; patients with an inadequate response (
ISSN:	1176-6328 1176-6328 1178-2021
DOI:	10.2147/NDT.S50248